James Paul Scopa Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for James Paul Scopa.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James Paul Scopa. James Paul Scopa is a Director in Conatus Pharmaceuticals Inc. ($CNAT) and a in TriVascular Technologies, Inc. ($TRIV) and a Director in TriVascular Technologies, Inc. ($TRIV) and a Director in Adverum Biotechnologies, Inc. ($ADVM) and a Director in Aligos Therapeutics, Inc. ($ALGS).
Address: 601 GATEWAY BLVD., SUITE 350 S. SAN FRANCISCO 94080 CA
Companies in which James Paul Scopa is an Insider
Adverum Biotechnologies, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of James Paul Scopa: Director
Holdings: 53,334 shares
Latest Transaction: May 14 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Aligos Therapeutics, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of James Paul Scopa: Director
Holdings: 0 shares
Latest Transaction: Apr 27 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Histogen Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of James Paul Scopa: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: Jun 25 2018
$HSTO Market Capitalization: $127.38M
$HSTO Previous Close: $5.00
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
TriVascular Technologies, Inc.
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of James Paul Scopa: Director
Holdings: 0 shares
Latest Transaction: Feb 04 2016
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of James Paul Scopa
Sentiment: All, ADVM, ALGS, HSTO, TRIV
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14 2021 | ADVM | Adverum Biotechnol ... | Scopa James Paul | Director | Option Exercise | A | 3.70 | 40,000 | 148,000 | 40,000 | |
| Apr 27 2021 | ALGS | Aligos Therapeutic ... | Scopa James Paul | Director | Option Exercise | A | 29.10 | 30,000 | 873,000 | 30,000 | |
| Jun 25 2020 | ADVM | Adverum Biotechnol ... | Scopa James Paul | Director | Option Exercise | A | 25.64 | 30,000 | 769,200 | 30,000 | |
| May 05 2020 | ADVM | Adverum Biotechnol ... | Scopa James Paul | Director | Option Exercise | M | 6.48 | 23,334 | 151,204 | 46,666 | |
| May 05 2020 | ADVM | Adverum Biotechnol ... | Scopa James Paul | Director | Buy | M | 6.48 | 23,334 | 151,204 | 53,334 | 30 K to 53.3 K (+77.78 %) |
| Feb 14 2020 | ADVM | Adverum Biotechnol ... | Scopa James Paul | Director | Buy | P | 13.75 | 10,000 | 137,500 | 30,000 | 20 K to 30 K (+50.00 %) |
| Aug 16 2019 | ADVM | Adverum Biotechnol ... | Scopa James Paul | Director | Option Exercise | A | 13.41 | 33,750 | 452,588 | 45,000 |